Stockwinners Market Radar for December 02, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:46 EST Iovance rallies after director buys $65M worth of shares - Iovance Biotherapeutics Director Wayne Rothbaum disclosed the purchase of 10M shares at a price of $6.50. The $65M of shares were purchased on December 2. Rothbaum now owns 18,067,333 shares of Iovance, which is up 10% to $7.49 in after-hours trading following the disclosure in a regulatory filing.

17:22 EST Cushman & Wakefield to replace Diebold in S&P 600 at open on 12/19

17:21 EST Agiliti to replace LL Flooring in S&P 600 at open on 12/19

17:19 EST Semtech to replace Diversified Healthcare Trust in S&P 600 at open on 12/19

17:18 EST Allegro MicroSystems to replace Semtech in S&P 400 at open on 12/19

17:04 EST Momentus announces resignation of CFO Jikun Kim - Momentus announced that Jikun Kim, Momentus CFO, will resign from his role effective January 6, 2023. Momentus will announce a successor for Kim at a later date. Kim joined Momentus in September 2020 as CFO. In this role, he led the company's accounting and financial planning and analysis group. He oversaw the company's Special Purpose Acquisition Company transaction that closed in August 2021 and the process of listing Momentus on the NASDAQ exchange.

17:00 EST AES Corp. raises quarterly dividend 5% to 16.59c per share - Payable on February 15, 2023 to shareholders of record at the close of business on February 1, 2023.

16:31 EST iBio announces resignation of CEO Thomas Isett - iBio announced the Board of Directors and Thomas Isett, the company's CEO, have agreed that Isett will resign as a member of the Board and relinquish his duties, rights and obligations as an officer and CEO of the company, effective immediately. While the company continues its search for a successor, the leadership team will report to the current Chair of the Board, William Clark.

16:28 EST Keurig Dr Pepper director Young sells 154,734 common shares - In a regulatory filing, Keurig Dr Pepper director Larry Young disclosed the sale of 154,734 common shares of the company on December 1 at a price of $38.67 per share.

16:20 EST XPO Logistics does not expect to divest European business near term - As previously announced on March 8, XPO plans to divest its European business through either a sale or a listing on a European stock exchange. Due primarily to weakened capital markets in Europe, the company does not currently expect to divest its European business in the near term. The company does not undertake to provide any further updates on the status of the plan, except as may be required by applicable law.

16:16 EST PNM Resources raises annual dividend payment 5.8% to $1.47 per share - The Board of Directors of PNM Resources voted to increase the company's annual dividend payment by 8c, a 5.8% increase, to an indicated annual rate of $1.47 per share of common stock. The increase reflects the third increase to the dividend during the company's pending merger. The board has declared the resulting quarterly stock dividend of 36.75c per share, payable February 17, 2023, to shareholders of record at the close of business February 3, 2023.

16:11 EST PotlatchDeltic raises quarterly distribution 2.3%, declares special dividend - The board of directors of PotlatchDeltic declared a Special Dividend on the company's common stock. The distribution of 95c per share is payable December 30 to stockholders of record on December 21. The board of directors of PotlatchDeltic also declared a quarterly distribution on the company's common stock. The distribution of 45c per share is payable December 30 to stockholders of record on December 14. This is a 2.3% increase compared to the prior quarterly dividend of 44c per share.

16:07 EST CalAmp names Jikun Kim, as SVP and CFO - CalAmp (CAMP) announced that effective January 9, 2023, Jikun Kim will commence employment as Senior Vice President and CFO. Kim will serve as principal financial officer and principal accounting officer. Xiaolian Zhang will cease service as Interim CFO, and will continue to serve as Senior Vice President, Financial Planning and Analysis, and Erik Schulz will cease service as Interim Principal Accounting Officer, and will continue to serve as Vice President and Corporate Controller. Kim currently serves as CFO of Momentus (MNTS), a position he has held since September 2020.

16:00 EST Venus Acquisition Corp trading resumes

15:21 EST BioVie Inc trading resumes

15:15 EST Cosmos Health reiterates 'belief and commitment to' company's financial strength - Cosmos Health, provided a summary regarding recent share activity, including the participation of CEO, Greg Siokas on all capital raises. "Management reiterates its belief in the financial strength of Cosmos Health, and its commitment to the growth and profitability of the company. In February and October of 2022 Cosmos successfully conducted two separate rounds of financings, with the combined proceeds of $13.5M. Furthermore, the company has noted significant exercises of warrants in the month of November. As such, management now expects that by the end of Year End 2022, debt should decline by roughly 50% versus prior year levels. Mr. Siokas has not sold any shares and has no plans to sell any of his shares," the company stated in a press release. CEO Greg Siokas added, "I am excited to see Cosmos emerge in to in a stronger financial position. We have had two successful capital raises in 2022, both of which I happily participated in for a combined amount of $3M. Since 2019, I have invested over $10.6M at an average price of $5.25 of my personal assets in Cosmos, as I have always believed in its growth and profitability prospects. My interests have always been and will continue to be aligned with those of shareholders, and I am constantly working to make sure shareholder value is realized. Given our new financial stability, I am hopeful about the future of Cosmos and our ability to rapidly grow as an international health and wellness company with multiple strong brands."

13:51 EST White House announces signing of railroad dispute resolution - On Friday, December 2, the President signed into law H.J. Res. 100, which provides for a resolution with respect to the unresolved disputes between certain railroads represented by the National Carriers' Conference Committee of the National Railway Labor Conference and certain of their employees, the White House announced. Publicly traded rail companies include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC) and Union Pacific (UNP). Reference Link

13:02 EST Baker Hughes reports U.S. rig count unchanged at 784 rigs - Baker Hughes reports that the U.S. rig count is unchanged from last week at 784 with oil rigs unchanged at 627, gas rigs unchanged at 155 and miscellaneous rigs unchanged at 2. The U.S. Rig Count is up 215 rigs from last year's count of 569 with oil rigs up 160, gas rigs up 53 and miscellaneous up 2. The U.S. Offshore Rig Count is up 1 to 18, up 5 year-over-year. The Canada Rig Count is up 1 from last week to 195, with oil rigs down 1 to 128, gas rigs up 2 to 67. The Canada Rig Count is up 15 rigs from last year's count of 180, with oil rigs up 15, gas rigs unchanged.

12:34 EST Digital Brands sees closing Sundry acquisition in next two weeks - Digital Brands Group announces that it expects to close the Sunnyside, LLC acquisition Friday, December 9th or Friday, December 16th. "The Sundry acquisition is expected to contribute significant revenue scale and operating leverage," said Hil Davis, CEO of DBG. "We believe adding Sundry to our Bailey Shop, which is our multi-brand e-commerce site will contribute revenue immediately. Additionally, we are also excited about the large opportunity to expand the Sundry brand into other verticals. We believe that the opportunity to cross merchandise Sundry and their customers to our other brands, add additional product categories and leverage synergies to reduce expenses will be accretive. "

12:01 EST Polished says Audit Committee concludes investigative process - Polished.com provided a status update on the investigation being carried out by the Audit Committee of the Board of Directors. The Audit Committee's independent legal counsel and advisors have concluded their investigative process. The Board of Directors is now assessing the results. The Company will disclose relevant and material findings upon concluding its evaluation, which it intends to do on an expedited basis.

12:00 EST Asana falls -11.8% - Asana is down -11.8%, or -$2.12 to $15.96.

12:00 EST Sunlands Online rises 20.4% - Sunlands Online is up 20.4%, or 92c to $5.43.

12:00 EST Samsara rises 21.9% - Samsara is up 21.9%, or $2.17 to $12.06.

11:34 EST Galaxy Digital intends to acquire self-custody platform GK8 - Galaxy Digital Holdings announced earlier that it intends to acquire GK8, an institutional digital asset self-custody platform. The acquisition will be the result of a sale process executed in connection with Celsius Network's Chapter 11 bankruptcy and is subject to court approvals and other closing conditions. Galaxy intends to support GK8's "ongoing operations in offering unique self-custody technology to the world's leading financial services firms, as well as utilize GK8's custody solution in the ongoing development of GalaxyOne." It added, "The transaction will accelerate Galaxy's product innovation and development by adding a team of nearly 40 people, including cryptographers and blockchain engineers. The deal will also expand Galaxy's geographic reach with the addition of an office in Tel Aviv."

11:03 EST JetBlue, Fidelis New Energy sign MOU for 92M gallons of SAF - JetBlue and Fidelis New Energy announced a memorandum of understanding to provide JetBlue at least 92 million gallons of blended sustainable aviation fuel from Fidelis' Gron Fuels GigaSystem at the Port of Greater Baton Rouge in Louisiana. This SAF is expected to be delivered over the five-year term with a targeted start date of 2025. With this MOU, Fidelis' negative carbon intensity SAF is helping JetBlue advance toward its goal to reach 10 percent of its total fuel usage as SAF on a blended basis by 2030. The SAF from the Gron Fuels GigaSystem is innovatively designed to achieve negative lifecycle carbon intensity by integrating carbon capture & sequestration and biomass energy with CCS.

10:02 EST Ovid Therapeutics to present data on epilepsy programs at AES Meeting - Ovid Therapeutics announced that preclinical data supporting its OV329 and OV350 programs in epilepsy and treatment-resistant seizures will be presented at the 2022 American Epilepsy Society Annual Meeting, taking place December 2-6 in Nashville, Tennessee. Using the NIH/NINDS Epilepsy Therapy Screening Program, a series of signal-finding studies using multiple mouse seizure models, found that OV329 demonstrated efficacy in the subacute models of epilepsy, including corneal kindling model and mesial temporal lobe epilepsy model, though it did not mitigate seizures in the 6 Hz psychomotor seizures and maximal electroshock seizures at the doses tested. In the CKM and MTLE models, a single, high dose of OV329 produced near-complete protection from seizure activity. This pattern is analogous to the effects of vigabatrin and supports additional studies to evaluate repeat dosing at lower dose levels in CKM models. Title: OV329, a next-generation GABA-AT inhibitor, suppresses hippocampal paroxysmal discharges following repeat dosing in a mouse model of mesial temporal lobe epilepsy. Summary: In the MTLE model, a once daily 3.0 mg/kg dose of OV329 administered for eight days significantly reduced the number of seizures by Day 4, with maximum reduction at Day 8, compared to baseline. Furthermore, changes in baseline seizures persisted for seven days following the last administration. Findings demonstrate repeat administration of 3.0 mg/kg is at least as efficacious as a single 10 mg/kg dose of OV329. Title: Direct activation of KCC2 with OV350 arrests refractory status epilepticus and limits the subsequent neuronal injury. Summary: OV350 binds with high affinity to KCC2, potassium chloride cotransporter isoform 2, and increases its activity, reducing neuronal Cl- accumulation and limiting the development of hyperexcitability. Additionally, OV350 restored the efficacy of benzodiazepines to treat refractory epilepsies and limit associated brain injuries. In addition, posters characterizing the mechanism of action of soticlestat and other supportive studies are anticipated to be presented by Takeda Pharmaceuticals. Ovid out-licensed soticlestat to Takeda, which is currently evaluating soticlestat in two pivotal, Phase 3 trials for Dravet and Lennox-Gastaut syndromes.

10:00 EST Modiv falls -9.6% - Modiv is down -9.6%, or -$1.55 to $14.55.

10:00 EST Smartsheet rises 15.6% - Smartsheet is up 15.6%, or $5.06 to $37.57.

10:00 EST Samsara rises 24.7% - Samsara is up 24.7%, or $2.45 to $12.35.

09:47 EST Modiv falls -9.0% - Modiv is down -9.0%, or -$1.45 to $14.65.

09:47 EST Smartsheet rises 13.6% - Smartsheet is up 13.6%, or $4.41 to $36.92.

09:47 EST Samsara rises 25.5% - Samsara is up 25.5%, or $2.52 to $12.42.

09:23 EST Coinbase says Apple blocked last app release on NFTs - In a series of Thursday tweets from its Coinbase Wallet account, Coinbase said, "You might have noticed you can't send NFTs on Coinbase Wallet iOS anymore. This is because Apple blocked our last app release until we disabled the feature...Apple's claim is that the gas fees required to send NFTs need to be paid through their In-App Purchase system, so that they can collect 30% of the gas fee...For anyone who understands how NFTs and blockchains work, this is clearly not possible. Apple's proprietary In-App Purchase system does not support crypto so we couldn't comply even if we tried...This is akin to Apple trying to take a cut of fees for every email that gets sent over open Internet protocols...The biggest impact from this policy change is on iPhone users that own NFTs - if you hold an NFT in a wallet on an iPhone, Apple just made it a lot harder to transfer that NFT to other wallets, or gift it to friends or family...Simply put, Apple has introduced new policies to protect their profits at the expense of consumer investment in NFTs and developer innovation across the crypto ecosystem...We hope this is an oversight on Apple's behalf and an inflection point for further conversations with the ecosystem. @apple - we're here and want to help". Reference Link

09:08 EST SeaStar Medical appoints Thomas Mullen as VP, operations, product development - SeaStar Medical Holding announced the appointment of Thomas Mullen as Vice President of Operations and Product Development. Since 1993, Mr. Mullen has led Mullen Business Development, a manufacturing, engineering and operations consulting firm. As VP, Operations and Product Development, Mr. Mullen will oversee the development and advancement of the Company's Selective Cytopheretic Device, a patented cell-directed extracorporeal therapy that works with continuous kidney replacement therapy systems to selectively target and reduce the inflammatory effects of activated neutrophils while transitioning pro-inflammatory monocytes to promote reparative processes. The SCD is currently being evaluated by the FDA for a Humanitarian Device Exemption marketing approval for use in children with acute kidney injury. The Company expects the FDA to complete a substantive review of its HDE application during the first quarter of 2023, with a potential commercial launch expected in the second quarter of 2023.

09:03 EST XFuels announces Cycle Oil & Gas update - Xfuels is pleased to report that Cycle Oil & Gas began overseeing operations in their Wichita County field effectively on July 1st, 2022, through the purchase of leases & property from Triple "S" Gas & Ray Loveless Enterprises. Cycle Oil & Gas contracted OAG Consulting Inc. of Fort Wort, Texas to conduct due diligence prior to purchase & manage their Texas operations after the purchase and sale agreement was completed. When Cycle was handed operational duties, they were met with a variety of challenges from the distressed assets. Production across all 17 leases was ~7bpd with most of the wells labeled "inactive" or "shut-in" by the TXRRC's standards. Josh Miller and the lease operators spent the months of July & August mitigating issues across the leases to increase runtime & reliability of their electrical infrastructure. Many of the properties had environmental concerns and time was spent on remediation to make sure the producing leases stayed within compliance with regulators at TXRRC. Cycle repaired multiple injection line leaks on their highest producing lease and weatherized electrical panels to allow for full capacity run time. Through these fixes, Cycle was able to increase production on this lease from 128bbls in August to 255bbls in September and have averaged 7.5bpd in the following months. Cycle currently has workovers planned for 5 shallow wells on its Burnett Gulf lease in December. Cycle believes that these wells simply need pump changes, which are a quick and inexpensive fix that should yield an additional 8-10bpd in production. Cycle will continue working over wells on a lease-by-lease basis until all 17 leases are operational. Cycle currently averages 12.5bpd as of Dec 1st, producing from 15 active wells. The company has continued to identify repairs that can increase production while being cost effective. Cycle also benefits from not having the added cost of hauling produced water off its leases for disposal and instead is able to inject produced water into their own injection wells. This allows for higher profit margins from production. To date; Cycle has increased monthly production from 231bbls per month in July & August, to an average of 345bbls per month since and is continuing to increase on a monthly basis. Cycle currently has over 125 shallow wells available to bring back into production through workovers and facility maintenance.

09:03 EST Uber Freight, Aurora Innovation announce expansion of autonomous pilot - Uber Freight (UBER) and Aurora Innovation (AUR) have announced the expansion of their autonomous pilot with a new commercial lane between Fort Worth and El Paso. The 600-mile lane across Texas launched in October and is supporting Uber Freight customers as they prepare for the 2022 holiday season.

09:02 EST Behr Paint Company partners with Nate Berkus, Jeremiah Brent - Behr Paint Company is thrilled to announce it has partnered with celebrity Interior Designers Nate Berkus and Jeremiah Brent to show how the Canadian BEHR Designer Collection palette can help DIYers transform any space. Berkus and Brent selected paint colours Tranquil Gray DC-007, Even Better Beige DC-010, and Behr's 2023 Colour of the Year, Blank Canvas DC-003, all shades from the BEHR Designer Collection palette, as their colours of choice.

09:01 EST LiqTech receives $500,000 order for filtration system - LiqTech International announced the receipt of a $0.5M order for a complete filtration system related to monoethylene glycol recovery in the oil & gas industry. This order is the first of a two-part order for an offshore project for a U.S. oil major operating in Europe. The system is expected to ship in 2023. The system will deploy LiqTech's robust silicon carbide membrane technology that offers unique technical advantages for this application. This is the first system order for this customer, who has identified several additional offshore sites as potential candidates for installations in 2023.

08:47 EST Altimeter Growth 2 announces liquidation - Last night, Altimeter Growth Corp. 2 announced that the company anticipates that the company cannot consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association and accordingly, the company intends to dissolve and liquidate in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association. As part of that dissolution and liquidation, the company will redeem all of the outstanding shares of Class A common stock that were included in its initial public offering at a per-share redemption price of approximately $10.11. As of the close of business on December 21, the public shares will represent the right to receive the redemption amount. Upon redemption such public shares will be deemed cancelled.

08:34 EST Xenon Pharmaceuticals provides updates on neurology programs at AES 2022 - Xenon Pharmaceuticals announced it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society, AES 2022. In addition, the Company is presenting results from the open label extension, OLE, and sub-analyses of data from the XEN1101 Phase 2b X-TOLE clinical trial. Poster No. 2.235 "XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2B Study in Adults With Focal Epilepsy" During the OLE, there was a sustained monthly reduction in seizure frequency from the double-blind period baseline, as of the analysis cutoff date of September 22, 2022. Seizure freedom for greater than or equal to 6-month and greater than or equal to12-month consecutive durations was achieved in 17.5% and 10.5% of patients, respectively. XEN1101 continues to be generally well-tolerated in the OLE with adverse events consistent with prior results and other anti-seizure medications. To date, two AEs of urinary retention occurred in the OLE possibly related to study drug; both patients continued in the study without requiring intervention. Poster No. 2.236 "Rapid Onset of Efficacy of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: Results From a Phase 2b Study" X-TOLE met the primary and key secondary efficacy endpoints with XEN1101 demonstrating a statistically significant, dose-dependent reduction from baseline in monthly focal onset seizure frequency compared to placebo. The rapid onset of efficacy for XEN1101 was associated with starting at an effective, therapeutic and well-tolerated dose. There was a statistically significant reduction in median FOS frequency within 1 week for all doses compared with placebo. The rapid onset of efficacy after 1 week and sustained efficacy of XEN1101, if confirmed in the Phase 3 clinical trials, suggests that XEN1101 may offer a compelling option for patients seeking adjunctive therapy. Poster No. 2.233 "The Impact of Disease Severity on Efficacy From a Phase 2b Study of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy" X-TOLE met the primary and key secondary efficacy endpoints with XEN1101 demonstrating a statistically significant, dose-dependent reduction from baseline in monthly FOS frequency compared to placebo in a difficult-to-treat population. Based on the number of concomitant ASMs, baseline seizure frequency, and number of failed ASMs, the X-TOLE study enrolled more difficult-to-treat patients than other FOS studies. In the 25 mg dose group, XEN1101 reduced seizure frequency in sub-groups of patients with less than or equal to 8.5 seizures/month, and in patients that failed less than or equal to 6 ASMs or were on 1-2 concomitant ASMs by 70.6%, 58.0% and 60.9%, respectively, compared with placebo

08:33 EST Urban Outfitters Group president Francis Pierrel departs - Urban Outfitters announced that Francis Pierrel, President, Urban Outfitters Group, has left the Company.

08:32 EST Gulf Resources announces buy back of shares from CEO, CFO, COO - Gulf Resource announced that the Company has entered into a stock repurchase agreement dated as of November 30, 2022, in which the Company agrees to purchase 80,000 shares from each of CEO Xiaobin Liu, COO, Chief Operating Officer, Naihui Miao, and CFO, chief financial officer, Min Li in a privately negotiated transaction based on the closing price of the stock of $3.5931 per share on Wednesday, November 30, 2022.The closing of the repurchase transactions is expected to occur in December 2022 and subject to customary closing conditions. The Company met with management and suggested that buying a block of stock from each of the three senior leaders may relieve some of the potential overhang. Accordingly, each of the three senior executives agreed to sell 80,000 shares of stock at this time to the Company. The retirement of these shares may also positively impact earnings and help to limited reduce some of the pressure from market.

08:23 EST CIBC 'disputes' liability ruling in Cerberus matter, intends to appeal - CIBC announced that a New York court issued a liability ruling against CIBC late in the afternoon on December 1, in a lawsuit brought by a special purpose vehicle controlled by Cerberus Capital Management L.P. The court has not determined any damages against CIBC and will hear the parties' arguments on damages at a hearing to be held on December 19. CIBC disputes the liability ruling and intends to appeal. The lawsuit, filed by Cerberus in November 2015, relates to an October 2008 transaction in which CIBC issued a limited recourse note to Cerberus specifying certain payment streams, and a subsequent transaction in 2011 in which CIBC sold a residual interest in the specified payment streams to Cerberus. At trial, Cerberus claimed damages of $1.067B. CIBC will vigorously dispute Cerberus' measure of damages at the hearing on December 19. CIBC had not set aside a provision for this matter in its year-end October 31 consolidated financial statements as it believed it was more likely than not to prevail at trial, but included a material amount for the matter in the range of reasonably possible losses for legal claims disclosed in aggregate in its consolidated financial statements. CIBC expects to recognize a provision in its first quarter 2023 results, the estimate of which will be informed by developments during the quarter.

08:13 EST Cracker Barrel falls 5% to $107.50 after Q1 results FY23 guidance

08:08 EST Credit Suisse rallies after Chairman says outflows 'basically stopped' - Credit Suisse Chairman Axel Lehmann said earlier during an interview with Bloomberg Television that the bank's liquidity was improving and the large outflows of client assets have "basically stopped." He added, "When I speak to clients, I already know that there are going to be inflows. We already see it partially happening. So we have plans to continue to reach out to clients. It might take a bit of time but it will come back and we will go back to normal." Shares of Credit Suisse are up 8% to $3.35 in premarket trading.

08:07 EST LendingClub acquires $1.05B loan portfolio - LendingClub announced an agreement to acquire a $1.05B loan portfolio. The portfolio consists of personal loans that were originated through LendingClub's marketplace and will support its growing revenue stream of recurring net interest income. The personal loans were previously acquired by MUFG Union Bank and became available for purchase following U.S. Bancorp's recently completed acquisition of MUFG Union Bank's core regional banking franchise. The loans are currently being serviced by LendingClub and have a current outstanding principal weighted average FICO score of 729.

08:06 EST Bausch Health wins DUOBRII, BRYHALI patent infringement case - Bausch Health Companies announced that the US District Court for the District of New Jersey issued a favorable decision regarding DUOBRII and BRYHALI, in a suit filed against Padagis Israel Pharmaceuticals LTD and Padagis US LLC. According to the ruling, the District Court found all the asserted patents valid and infringed. The current decision will serve to prevent approval of Padagis BRYHALI and DUOBRII generics until patent expiry in 2031 and 2036, respectively.

08:05 EST Mirati Therapeutics provides update on Phase 3 SAPPHIRE study - Mirati Therapeutics announced that based on the results of an interim analysis on overall survival, the registrational Phase 3 study evaluating sitravatinib in combination with nivolumab in patients with second or third line non-squamous non-small cell lung cancer who have acquired resistance to prior therapy with chemotherapy and immune checkpoint inhibitor therapy will continue to the study's final analysis. The final analysis is expected to be reached in mid-2023. "We remain committed to developing our portfolio of oncology candidates and advancing our lung cancer strategy to positively impact the lives of patients with cancer. We look forward to providing an update based on the full analysis of the SAPPHIRE study in mid-2023," said Charles Baum, M.D., Ph.D., president, founder and head of research and development, Mirati Therapeutics.

08:03 EST EQRx announces acceptance of MAA by EMA for aumolertinib - EQRx announced that the European Medicines Agency has accepted for review its marketing authorization application for aumolertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor in development for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGFR mutations, and for adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. The MAA is primarily supported by data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib in the first-line treatment of locally advanced or metastatic EGFR-mutated NSCLC. This is EQRx's second submission to a regulatory agency for aumolertinib. Aumolertinib's MAA for use in EGFR-mutated non-small cell lung cancer is currently under review by the UK's Medicines and Healthcare products Regulatory Agency.

07:57 EST Sanofi says any offer for Horizon Therapeutics, if made, to be 'solely in cash' - Sanofi (SNY) issued the following statement regarding rule 2.12 of the takeover rules: "Sanofi S.A. confirms that any offer for Horizon Therapeutics plc, if made by Sanofi, will be solely in cash. There is no certainty that any offer will be made, nor as to the terms on which any such offer may be made, if forthcoming."

07:45 EST Lottery.com's Sports.com partners with Saudi Motorsport Company - Lottery.com announced that its wholly owned subsidiary Sports.com has entered into a strategic partnership with the Saudi Motorsport Company to coincide with activity around the FIA World Touring Car Cup decider, which was held in Jeddah, Saudi Arabia last weekend, from 25- - 27 November 2022. As part of the agreement, Sports.com branding and advertising was displayed around the track for the duration of the competition, setting the foundation for the future establishment of a joint venture and content distribution partnership.

07:36 EST AirBoss of America announces intention to renew normal course issuer bid - AirBoss of America announced today that the Toronto Stock Exchange has accepted its Notice of Intention to renew its normal course issuer bid for its common shares. Purchases made pursuant to the Bid will be made in the open market through the facilities of the TSX and alternative Canadian trading systems, if eligible, in accordance with applicable regulatory requirements. For its current Bid that expires on December 5, 2022, the Company previously sought and received approval from the TSX to repurchase up to 500,000 common shares. The Company has not purchased common shares for cancellation to date over the course of the current Bid. Pursuant to the renewed Bid, the Company may re-purchase up to 500,000 of its common shares. The renewed Bid will commence on December 6, 2022 and remain in effect until the earlier of December 5, 2023, the termination of the Bid by the Company or the Company purchasing the maximum number of common shares permitted under the Bid. As of November 28, 2022, the Company had 27,092,041 common shares issued and outstanding. Subject to the Company's ability to make "block" purchases through the facilities of the TSX, the maximum number of common shares that the Company may purchase on any trading day is 41,162 common shares (representing 25% of 164,648, being the average daily trading volume of the Company's shares on the TSX in the six month period prior to the Bid). The price paid for any common shares acquired by the Company will be the market price of the shares at the time of acquisition. The Company intends to fund the repurchases under the Bid out of its available cash. All common shares acquired by the Company under the Bid will be cancelled.

07:34 EST FTI Consulting announces $400M stock repurchase authorization - FTI Consulting announced that on December 1, 2022, FTI Consulting's Board of Directors authorized the additional amount of $400M to repurchase its outstanding shares of common stock under its stock repurchase program. As of November 30, 2022, FTI Consulting has repurchased approximately 11.3M shares of its outstanding common stock pursuant to its stock repurchase program at an average price per share of $70.93 for an aggregate cost of approximately $799.M. After giving effect to share repurchases through that date and the increased authorization, FTI Consulting has approximately $501M remaining available for common stock repurchases under its program.

07:33 EST Immunocore, Gadeta announce agreement to develop gamma delta TCR ImmTAC - Immunocore and Gadeta B.V announced that they will collaborate on the first gammadelta ImmTAC for solid tumors, including colorectal cancer. "Immunocore pioneered TCR therapy with the launch of KIMMTRAK and we continue to push the edge of TCR science, including researching non-HLA restricted TCR therapies, both internally and through collaborations that complement our platform," said David Berman, Head of Research and Development of Immunocore. "We are very pleased to collaborate with Gadeta to combine their expertise in gamma delta TCRs with our scientific, development, and commercialization capabilities to deliver new TCR therapies." Under the terms of the agreement, Immunocore and Gadeta will collaborate on '201 gammadelta-TCR target discovery, and Immunocore will have the option to develop ImmTAC therapies derived from the '201 TCR as part of the research collaboration. Immunocore has an option for an exclusive license to further research, develop and commercialize an ImmTAC candidate from the collaboration. Gadeta is eligible to receive upfront, near-term option fee and research milestone payments.

07:32 EST Owens Corning announces dividend increase, new share repurchase authorization - Owens Corning announced that its board of directors has approved a quarterly dividend increase and new share repurchase authorization. The actions reaffirm the company's capital allocation strategy and reflect the success of its disciplined commercial and operational execution to deliver sustainable performance in a dynamic macro-economic environment. The board has declared a quarterly cash dividend of 52c per common share, an approximately 50% increase compared with the prior quarterly dividend. The dividend will be payable on January 19, 2023, to shareholders of record as of January 4, 2023. In addition, the board of directors has approved a share repurchase authorization for up to 10 million shares of the company's common stock. This is in addition to the previously announced share buyback program in which approximately 7.4M shares remained available for purchase as of September 30. The authorization enables the company to repurchase shares through open-market, privately negotiated, or other transactions. The actual number of shares repurchased will depend on timing, market conditions, and other factors, and will be at the company's discretion. During the first nine months of 2022, the company returned $639 million to shareholders through share repurchases and dividends.

07:27 EST NRx Pharmaceuticals regains compliance with Nasdaq - NRx Pharmaceuticals announced it received written notice on December 1 from The Nasdaq Stock Market informing NRx Pharmaceuticals that it has regained compliance with the minimum bid price requirement under the Nasdaq Listing Rule 5450 and the matter is now closed. Nasdaq staff made this determination after NRx Pharmaceuticals' closing bid price was above $1.00 per share for 10 consecutive business days from November 16 to November 30.

07:05 EST Syndax names Steve Sabus as Chief Commercial Officer - Syndax Pharmaceuticals announced the appointment of Steve Sabus to the role of Chief Commercial Officer, effective December 5. Sabus brings to Syndax more than 30 years of commercial experience launching drugs and building sales and marketing organizations within the biopharmaceutical industry. As Chief Commercial Officer, Sabus will oversee all commercial functions, including the development of critical launch initiatives, sales planning and commercial strategy. Prior to joining Syndax, Sabus served as Chief Commercial Officer at Turning Point Therapeutics, before being acquired by BMS.

07:02 EST Kirkland's CEO sees FY23 as 'a year of stabilization' for the company - "In the third quarter, we made progress re-engaging with our customers and reported results in-line with our internal expectations," said Steve "Woody" Woodward, president and CEO of Kirkland's Home. "We experienced an encouraging rebound in sales through August and our Labor Day promotional event, but we believe persistent macro-economic pressures hampered our customers during the Harvest selling season, resulting in softer sales for the back half of the quarter. Although the consumer environment was volatile, we continued to execute initiatives within our control to improve our liquidity position and enhance our overall margin profile. Sales trends have improved thus far in the fourth quarter as customers have responded favorably to our holiday merchandise offering. We expect the environment to remain promotional for the balance of the quarter as we rationalize our inventories for 2023. We've made good initial progress reducing inventories, and we have already made a substantial reduction in our borrowings. Additionally, supply chain disruptions have eased, and inbound freight rates have declined. While we won't see a significant benefit from these factors until we've worked through our current inventory, we expect it to show in our merchandise margin in fiscal 2023 and beyond. Overall, we believe fiscal 2023 will be a year of stabilization for our organization. We are well on track to hit our targets of meaningfully paying down our credit line and reducing our inventories, which should provide us a healthier balance sheet as we move into next year. While the broader consumer environment is difficult to predict, we are focused on stabilizing our store comps, increasing e-commerce sales and maintaining strict cost control measures to improve the overall profitability of our platform. This will allow us to further invest in future sales growth initiatives. We believe there is immense value to still be unlocked from Kirkland's Home, and we look forward to delivering long-term value for our shareholders."

06:55 EST Consol Energy CEO sells $1.2M in common stock - In a regulatory filing, Consol Energy disclosed that its CEO James Brock sold 15.8K shares of common stock on November 29th in a total transaction size of $1.2M

06:41 EST Beam Therapeutics jumps 11% to $51.00 after FDA lifts hold on IND for BEAM-201

06:31 EST Beam Therapeutics: FDA lifts clinical hold on IND application for BEAM-201 - Beam Therapeutics announced the U.S. FDA has lifted the clinical hold and cleared the Investigational New Drug application for BEAM-201 for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma. BEAM-201 is a potent and specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development candidate.

06:04 EST Ensign Group acquires two skilled nursing facilities in Colorado - The Ensign Group announced that it acquired the operations of Brighton Care Center, a 108-bed skilled nursing facility located in Brighton, Colorado, and Malley Transitional Care Center, a 162-bed skilled nursing facility located in Northglenn, Colorado. These acquisitions were effective December 1 and will be subject to a long-term, triple net lease.

05:28 EST Fortune Brands to acquire four brands from Assa Abloy for $800M - Fortune Brands (FBHS) announced it has entered into a definitive agreement to acquire the Emtek and Schaub premium and luxury door and cabinet hardware business and the U.S. and Canadian Yale and August residential smart home locks business from Assa Abloy (ASAZY) for a purchase price of $800M, or approximately $700M net of tax benefits, in cash on a cash-free, debt-free basis, subject to customary adjustments. With revenues of approximately $350M in 2021, the business is comprised of brands in the smart lock and the highly profitable and growing premium and luxury hardware categories. Fortune Brands expects to add meaningful growth and cost synergies to the Business over time. Fortune Brands expects to receive tax benefits over a 15-year period with a net present value of approximately $100M, and the net purchase price of $700M equates to approximately 7.8x estimated 2022 adjusted EBITDA for the business before synergies. The acquisition is conditioned on the successful closing of the acquisition by Assa Abloy from Spectrum Brands (SPB) of its Hardware and Home Improvement business following a favorable resolution of the court proceedings with the Department of Justice. The acquisition is expected to close in the second quarter of 2023.

05:18 EST Constellium to lead group to develop lower carbon, lower cost aluminum alloys - Constellium announced that it is leading a new consortium of automakers and suppliers to develop lower carbon, lower cost aluminum extrusion alloys. Sponsored by a grant from the UK's Advanced Propulsion Centre, or APC, the GBP 10M CirConAl project aims to maximize the use of post-consumer scrap in a new generation of high-strength alloys that emit less than two tons of CO2 per ton of aluminum produced. CirConAl is part of joint government and industry support for projects to build an end-to-end supply chain for zero-emissions vehicles in the UK. By designing, developing, prototyping, and testing aluminium automotive components at scale, the project is expected to demonstrate that high-strength alloys with high recycled content can meet or exceed OEM requirements, such as strength, crushability, durability, and other performance criteria. Together, the partners would also develop scrap sorting technologies to ensure that valuable metal is recycled into new automotive solutions rather than downcycled, preserving its value and contributing to a circular economy.

05:13 EST Tremor to act as CTV monetization platform across Vidaa, Google TV devices - Vidaa and a subsidiary of Hisense announced an agreement for Google TV (GOOGL) and other Android TV OS devices to carry Vidaa's premium sports content, which includes FIFA+. As a long-term partner of Vidaa, Tremor International (TRMR) will act as the exclusive global CTV monetization platform - specifically Tremor's SSP, Unruly - for the content across all Vidaa and Android TV OS devices. The premium content includes the FIFA+ app, with thousands of hours of original, live and archive football and original programming, and The FIFA World Cup Daily, By Hisense, a new daily show filmed on-site and airing throughout the tournament.